An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients

Study acronym: PRESENTII
StatusCompleted
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 4 more changesShow less
    • Study sites: 30 to 29
    • Primary and study completion dates changed from estimate of Sep 30, 2026 to Sep 1, 2026
    • Eligibility criteria expanded, about 7 words
    • Study description revised
  2. 3 versions Re-verified since Jan 19, 2026, no change to tracked fieldsv11-v13
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 200 to confirmed 202
    • Study sites: 31 to 30
    v10
  4. Site details revised at 2 of 31 sitesv9
  5. Study sites: 32 to 31v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 37 to 32v7
  2. 2 versions Re-verified since Mar 13, 2025, no change to tracked fieldsv5-v6
  3. Study sites: 35 to 37v4
  4. Re-verified, no change to tracked fieldsv3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 35
    • Start date changed from estimate of Nov 30, 2024 to Nov 14, 2024
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
732 trials monitored
See 61 trials at risk
Asthma
959 trials monitored
See 36 trials at risk
This study is a multicenter, observational, prospective study to evaluate the asthma biologic use features and clinical outcomes in China. Patients will undergo clinical assessments and receive standard medical care as determined by the treating physician.
Trial Details
NCT Number NCT06605885
Lead Sponsor AstraZeneca
Conditions
(from sponsor)		 Asthma
Related terms Asthma
Enrollment 202 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov